Huaxiang Wu Selected Research

Certolizumab Pegol

3/2019

Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Huaxiang Wu Research Topics

Disease

11	Rheumatoid Arthritis 09/2023 - 08/2013
9	Gout 11/2023 - 07/2014
6	Ankylosing Spondylitis 03/2022 - 03/2014
5	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2023 - 11/2019
2	Hyperuricemia 05/2024 - 01/2020
2	Fibrosis (Cirrhosis) 03/2024 - 01/2022
2	Inflammation (Inflammations) 01/2023 - 03/2019
2	Spondylarthropathies 03/2022 - 10/2013
2	Arthritis (Polyarthritis) 07/2019 - 03/2017
2	Gouty Arthritis 03/2017 - 07/2014
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 05/2024
1	Macrophage Activation Syndrome 11/2023
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 11/2023
1	Axial Spondyloarthritis 09/2023
1	Tuberculosis (Tuberculoses) 01/2023
1	Starvation 01/2023
1	Insulin Resistance 12/2022
1	Chronic Renal Insufficiency 10/2022
1	Dermatomyositis (Dermatopolymyositis) 01/2022
1	Systemic Scleroderma (Systemic Sclerosis) 01/2022
1	Osteoarthritis 01/2022
1	Lung Diseases (Lung Disease) 01/2022
1	Antisynthetase syndrome 01/2022
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2022
1	Chronic Disease (Chronic Diseases) 01/2022
1	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022
1	Fatigue 01/2022
1	Behcet Syndrome (Behcet's Syndrome) 12/2021
1	Autoimmune Diseases (Autoimmune Disease) 02/2021
1	Disease Progression 01/2021
1	Sjogren's Syndrome (Sjogren Syndrome) 01/2021
1	Insulinoma 01/2020
1	Back Pain (Backache) 01/2020
1	Experimental Arthritis 07/2019
1	Joint Diseases (Joint Disease) 10/2013
1	Lipoma (Lipomata) 10/2013

Drug/Important Bio-Agent (IBA)

10	Uric Acid (Urate)IBA 11/2023 - 07/2014
6	Biosimilar PharmaceuticalsIBA 10/2022 - 01/2020
5	Biomarkers (Surrogate Marker)IBA 09/2023 - 01/2020
4	Adalimumab (Humira)FDA Link 03/2022 - 03/2014
3	Immunoglobulins (Immunoglobulin)IBA 02/2021 - 01/2018
2	MicroRNAs (MicroRNA)IBA 11/2023 - 01/2022
2	Antirheumatic Agents (DMARD)IBA 09/2023 - 10/2013
2	Semaphorins (Semaphorin)IBA 03/2023 - 01/2022
2	Rituximab (Mabthera)FDA Link 01/2023 - 10/2022
2	GlucocorticoidsIBA 01/2023 - 12/2021
2	Methotrexate (Mexate)FDA LinkGeneric 10/2022 - 03/2019
2	ametantrone (HAQ)IBA 03/2022 - 01/2022
2	Interleukin-6 (Interleukin 6)IBA 01/2022 - 01/2020
2	Etanercept (Enbrel)FDA Link 03/2021 - 01/2020
2	Long Noncoding RNAIBA 01/2021 - 01/2021
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2013 - 08/2013
1	Anthocyanins (Anthocyanin)IBA 05/2024
1	AntioxidantsIBA 05/2024
1	FlavonoidsIBA 05/2024
1	Bleomycin (Blenoxane)FDA LinkGeneric 03/2024
1	Interferon Type IIBA 11/2023
1	Colchicine FDA LinkGeneric 11/2023
1	Interleukin-17 (Interleukin 17)IBA 09/2023
1	ixekizumabIBA 09/2023
1	Tumor Necrosis Factor InhibitorsIBA 09/2023
1	Leflunomide (Arava)FDA LinkGeneric 01/2023
1	Cell-Free Nucleic AcidsIBA 01/2023
1	NitrogenIBA 01/2023
1	Pancreatic Elastase (Elastase)IBA 01/2023
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2023
1	CytokinesIBA 01/2023
1	Tacrolimus (Prograf)FDA LinkGeneric 01/2023
1	Calcium Carbonate (Limestone)FDA Link 01/2023
1	Leukocyte Elastase (Neutrophil Elastase)IBA 01/2023
1	LipidsIBA 12/2022
1	Febuxostat FDA Link 10/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	Matrix Metalloproteinase 13IBA 12/2021
1	Azathioprine (Imuran)FDA LinkGeneric 12/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	bergeninIBA 01/2020
1	Indicators and Reagents (Reagents)IBA 01/2020
1	Scavenger Receptors (Scavenger Receptor)IBA 01/2020
1	Small Interfering RNA (siRNA)IBA 01/2020
1	Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA 07/2019
1	CollagenIBA 07/2019
1	Certolizumab Pegol FDA Link 03/2019
1	tufulingIBA 03/2017
1	Infliximab (Remicade)FDA Link 08/2013
1	Monoclonal AntibodiesIBA 08/2013

Therapy/Procedure

10	Therapeutics 01/2023 - 08/2013
1	Endovascular Procedures 11/2023
1	Remission Induction 01/2023